Most experience exists for sitagliptin (Merck) and vildagliptin (Novartis), which both have a long duration of action, allowing once-daily administration. In drug-naïve subjects with type 2 ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and role in therapy of vildagliptin for the treatment of type 2 diabetes mellitus were reviewed.

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

A recently published study examined the effects of adding sitagliptin—an inhibitor of dipeptidyl peptidase 4—to therapy for patients with type 2 diabetes mellitus who were inadequately ...